FDA Draft Guidance Should Focus on "Companion Biomarkers" and Provide
FDA Draft Guidance Should Focus on "Companion Biomarkers" and Provide for Use of LDTs
The Association for Molecular Pathology (AMP) submitted comments to the Food and Drug Administration (FDA) regarding the FDA's "Draft Guidance for Industry and Food and Drug Administration Staff - In Vitro Companion Diagnostic Devices".